Research may provide missing link in search for Parkinson's disease therapeutics

Parkinson's disease (PD), a chronic, progressive and devastating neurodegenerative motor disease affecting as many as one million Americans, is complex. Its causes likely include a combination of genetic, environmental and other lifestyle factors that influence gene expression. While progress has been made, a fundamental understanding of how the disease develops on the molecular level is still lacking, due in large part because there is no good way to model the disease. Research from the Buck Institute is poised to change that. Buck Institute faculty Xianmin Zeng, PhD, has derived 10 induced pluripotent stem cells (iPSC) lines from PD patients and is in the process of depositing those lines along with a wealth of related genomic information about them into an NIH-approved facility for use by the larger research community. Details about the iPSC lines will publish in PLOS One on Wednesday, May 18.

"We think this is the largest collection of patient-derived lines generated at an academic institute," said Zeng, who is also developing a stem cell replacement therapy for PD. "We believe the lines and the datasets we have generated from them will be a valuable resource for use in modeling PD and for the development of new therapeutics." Given the aging of the population and the fact that current therapies only address symptoms, the need for a relevant disease model for PD is urgent. Affected neurons cannot be obtained from PD patients (except for post-mortem tissue which has limited value) and Zeng says animal studies, while valuable often provide an inadequate representation of what occurs in human patients.

Read More>>

Featured Posts
Recent Posts
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square